Insider Trading Alert - OMED, ALQA And SNBC Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 20, 2015, 100 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $186.58 to $190,703,600.00.

Highlighted Stocks Traded by Insiders:

OncoMed Pharmaceuticals (OMED) - FREE Research Report

Gurney Austin, who is Officer at OncoMed Pharmaceuticals, sold 4,000 shares at $22.48 on May 20, 2015. Following this transaction, the Officer owned 63,419 shares meaning that the stake was reduced by 5.93% with the 4,000-share transaction.

The shares most recently traded at $22.61, up $0.13, or 0.6% since the insider transaction. Historical insider transactions for OncoMed Pharmaceuticals go as follows:

  • 4-Week # shares bought: 3,170
  • 4-Week # shares sold: 1,887
  • 12-Week # shares bought: 3,170
  • 12-Week # shares sold: 9,887
  • 24-Week # shares bought: 3,170
  • 24-Week # shares sold: 21,887

The average volume for OncoMed Pharmaceuticals has been 148,800 shares per day over the past 30 days. OncoMed Pharmaceuticals has a market cap of $681.4 million and is part of the health care sector and drugs industry. Shares are up 5.38% year-to-date as of the close of trading on Wednesday.

OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, discovers and develops protein therapeutics targeting cancer stem cells (CSCs). Currently, there are 3 analysts who rate OncoMed Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OMED - FREE

TheStreet Quant Ratings rates OncoMed Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full OncoMed Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Biotech Movers: Horizon, OncoMed, Inovio

Wall Street Ends Its Losing Streak As Corporate Earnings Take Focus

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Stocks Higher Ahead of Earnings From Netflix, United Airlines

Stocks Higher as Wall Street Focuses on Earnings and Mixed Economic Data